Navigating chemical space for biology and medicine
暂无分享,去创建一个
[1] P. Andrews,et al. Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.
[2] S. van Gestel,et al. Thirty‐three years of drug discovery and research with Dr. Paul Janssen , 1986 .
[3] Barry A. Bunin,et al. A general and expedient method for the solid-phase synthesis of 1,4-benzodiazepine derivatives , 1992 .
[4] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[5] W. Sneader. Drug prototypes and their exploitation , 1996 .
[6] G. Rishton. Reactive compounds and in vitro false positives in HTS , 1997 .
[7] Ajay,et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.
[8] P. Schleyer. Encyclopedia of computational chemistry , 1998 .
[9] S. Schreiber. Chemical genetics resulting from a passion for synthetic organic chemistry. , 1998, Bioorganic & medicinal chemistry.
[10] P. Kollman,et al. Encyclopedia of computational chemistry , 1998 .
[11] C. Crews,et al. Chemical genetics: exploring and controlling cellular processes with chemical probes. , 1999, Trends in biochemical sciences.
[12] Ajay,et al. Recognizing molecules with drug-like properties. , 1999, Current opinion in chemical biology.
[13] J. Wang,et al. Toward designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds. , 1999, Journal of combinatorial chemistry.
[14] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[15] T. Raju. The Nobel Chronicles , 2000, The Lancet.
[16] R. Stroud,et al. Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[17] Vicki L. Nienaber,et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.
[18] T. Raju,et al. The Nobel Chronicles , 2000, The Lancet.
[19] C. Rader,et al. Antibody libraries in drug and target discovery. , 2001, Drug discovery today.
[20] I. Muegge,et al. Simple selection criteria for drug-like chemical matter. , 2001, Journal of medicinal chemistry.
[21] Darren V. S. Green,et al. Prediction of Biological Activity for High-Throughput Screening Using Binary Kernel Discrimination , 2001, J. Chem. Inf. Comput. Sci..
[22] M. G. Finn,et al. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. , 2001, Angewandte Chemie.
[23] I. Muegge,et al. Computational methods to estimate drug development parameters. , 2001, Current opinion in drug discovery & development.
[24] R. Dolle. Comprehensive survey of combinatorial library synthesis: 2000. , 2001, Journal of combinatorial chemistry.
[25] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[26] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[27] Tudor I. Oprea,et al. Chemography: the Art of Navigating in Chemical Space , 2000 .
[28] Robert Schweitzer,et al. Comparison of Assay Technologies for a Tyrosine Kinase Assay Generates Different Results in High Throughput Screening , 2002, Journal of biomolecular screening.
[29] Rudi Verbeeck,et al. Outlier Mining in High Throughput Screening Experiments , 2002, Journal of biomolecular screening.
[30] Harren Jhoti,et al. High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.
[31] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[32] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[33] J. Proudfoot. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. , 2002, Bioorganic & medicinal chemistry letters.
[34] R. Griffey,et al. SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. , 2002, Journal of medicinal chemistry.
[35] Tudor I. Oprea,et al. Chemical space navigation in lead discovery. , 2002, Current opinion in chemical biology.
[36] Walters Wp,et al. Guiding molecules towards drug-likeness. , 2002 .
[37] M. Murcko,et al. Guiding molecules towards drug-likeness. , 2002, Current opinion in drug discovery & development.
[38] K. Shokat,et al. Novel chemical genetic approaches to the discovery of signal transduction inhibitors. , 2002, Drug discovery today.
[39] R. Remmele,et al. Designing proteins that work using recombinant technologies. , 2002, Current pharmaceutical biotechnology.
[40] Jean-Pierre Marquette,et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. , 2002, Journal of medicinal chemistry.
[41] W Patrick Walters,et al. Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.
[42] Hans-Joachim Böhm,et al. A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.
[43] G. Rishton. Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.
[44] I. Muegge. Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.
[45] J Fraser Glickman,et al. Comparison of Assay Technologies for a Nuclear Receptor Assay Screen Reveals Differences in the Sets of Identified Functional Antagonists , 2003, Journal of biomolecular screening.
[46] Roland E Dolle,et al. Comprehensive survey of combinatorial library synthesis: 2002. , 2003, Journal of combinatorial chemistry.
[47] David F. Horrobin,et al. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.
[48] H. Kolb,et al. The growing impact of click chemistry on drug discovery. , 2003, Drug discovery today.
[49] S. Teague. Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.
[50] A. Sands,et al. Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.
[51] A L Hopkins,et al. Target analysis: a priori assessment of druggability. , 2003, Ernst Schering Research Foundation workshop.
[52] Brian K Shoichet,et al. Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.
[53] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[54] Michael Williams. A return to the fundamentals of drug discovery? , 2004, Current opinion in investigational drugs.
[55] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[56] Richard Morphy,et al. From magic bullets to designed multiple ligands. , 2004, Drug discovery today.
[57] D. Swinney,et al. Biochemical mechanisms of drug action: what does it take for success? , 2004, Nature Reviews Drug Discovery.
[58] A. Sands,et al. Modeling drug action in the mouse with knockouts and RNA interference , 2004 .
[59] Michael S Lajiness,et al. Molecular properties that influence oral drug-like behavior. , 2004, Current opinion in drug discovery & development.
[60] Nicolas Foloppe,et al. Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totalling 2.7 Million Compounds , 2004, J. Chem. Inf. Model..
[61] G. Hannon,et al. Unlocking the potential of the human genome with RNA interference , 2004, Nature.
[62] James R Horn,et al. Allosteric inhibition through core disruption. , 2004, Journal of molecular biology.
[63] T. Insel,et al. NIH Molecular Libraries Initiative , 2004, Science.
[64] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[65] C. Wermuth. Selective optimization of side activities: another way for drug discovery. , 2004, Journal of medicinal chemistry.
[66] Ian A. Watson,et al. Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.
[67] Daniel A Erlanson,et al. Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.
[68] T. Rabbitts,et al. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. , 2004, Current molecular medicine.